Study shows PICS as bioequivalent to Abraxane to treat breast cancer: SPARC
Team Udayavani, Nov 26, 2018, 12:54 PM IST
New Delhi: Sun Pharma’s research arm Sun Pharma Advanced Research Company (SPARC) Monday announced top-line results of the pivotal BE study for its Paclitaxel injection concentrate for suspension (PICS) which has been found to be a bioequivalent to Abraxane, used to treat metastatic breast cancer.
Paclitaxel injection concentrate for suspension (PICS) is a novel formulation of Paclitaxel developed using SPARC’s proprietary Nanotecton technology.
The company said it is targeting a new drug application with the US health regulator in the next few months. “Pivotal bioequivalence (BE) ,” SPARC said in a regulatory fling.
SPARC CEO Anil Raghavan said overall US Paclitaxel market is estimated to be about USD 700 million (IQVIA MAT Sep 2018). The current market is dominated by Cremophor-based Paclitaxel formulations, which accounts for 70 per cent of unit sales.
“With launch of novel formulations, market for nano-formulations of Paclitaxel is expected to grow,” he added. Shares of SPARC were trading 2.15 per cent at Rs 278.05 apiece on BSE.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Why not detect sex of foetus, then protect girl child: IMA chief Asokan
Include 4 hrs of physical activity, 8 hrs sleep in routine for optimal health, suggests study
Traffic noise can increase risk of cardiovascular disease: Study
Nearsightedness is at epidemic levels – and the problem begins in childhood
Study finds genetic basis for link between depression, heart disease
MUST WATCH
Latest Additions
Hardik Pandya and MI penalised heavily after loss to LSG
Congress using fear, rumour and now deepfake for its propaganda: Anurag Thakur
5 Delhi schools receive bomb threats, searches underway
‘Regularly working’ with India in probe on alleged plot to kill Sikh separatist leader: US
SIT issues notice to Revanna, Prajwal Revanna in sexual harassment case